Evidence map›Paper›PMID 30186743›Full record

ArticleFEBS open bio2018

Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation.

Yoshiji Hantani, Kiyosei Iio, Rie Hantani, Kayo Umetani, Toshihiro Sato, Tracy Young, Katelyn Connell, Sam Kintz, Joshua Salafsky

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yoshiji HantaniBiological/Pharmacological Research Laboratories Central Pharmaceutical Research Institute Japan Tobacco Inc. Takatsuki Osaka Japan.
Kiyosei IioChemistry Research Laboratories Central Pharmaceutical Research Institute Japan Tobacco Inc. Takatsuki Osaka Japan.
Rie HantaniBiological/Pharmacological Research Laboratories Central Pharmaceutical Research Institute Japan Tobacco Inc. Takatsuki Osaka Japan.
Kayo UmetaniBiological/Pharmacological Research Laboratories Central Pharmaceutical Research Institute Japan Tobacco Inc. Takatsuki Osaka Japan.
Toshihiro SatoBiological/Pharmacological Research Laboratories Central Pharmaceutical Research Institute Japan Tobacco Inc. Takatsuki Osaka Japan.
Tracy YoungBiodesy, Inc. South San Francisco CA USA.
Katelyn ConnellBiodesy, Inc. South San Francisco CA USA.
Sam KintzBiodesy, Inc. South San Francisco CA USA.
Joshua SalafskyBiodesy, Inc. South San Francisco CA USA.
Japan Tobacco (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many clinically approved protein kinase inhibitors stabilize an inactive conformation of their kinase target. Such inhibitors are generally highly selective compared to active conformation inhibitors, and consequently, general methods to identify inhibitors that stabilize an inactive conformation are much sought after. Here, we have applied a high-throughput, second-harmonic generation (SHG)-based conformational approach to identify small molecule stabilizers of the inactive conformation of interleukin-2-inducible T-cell kinase (ITK). A single-site cysteine mutant of the ITK kinase domain was created, labeled with an SHG-active dye, and tethered to a supported lipid bilayer membrane. Fourteen tool compounds, including stabilizers of the inactive and active conformations as well as nonbinders, were first examined for their effect on the conformation of the labeled ITK protein in the SHG assay. As a result, inactive conformation inhibitors were clearly distinguished from active conformation inhibitors by the intensity of SHG signal. Utilizing the SHG assay developed with the tool compounds described above, we identified the mechanism of action of 22 highly selective, inactive conformation inhibitors within a group of 105 small molecule inhibitors previously identified in a high-throughput biochemical screen. We describe here the first use of SHG for identifying and classifying inhibitors that stabilize an inactive vs. an active conformation of a protein kinase, without the need to determine costructures by X-ray crystallography. Our results suggest broad applicability to other proteins, particularly with single-site labels reporting on specific protein movements associated with selectivity.

Indexed as

biosensordrug discoveryinactive kinaseinterleukin‐2‐inducible T‐cell kinasesecond‐harmonic generationsurface plasmon resonance

Identifiers

PMID30186743
PMCPMC6120236
OpenAlexW2866550058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.